SGLT2i safety in kidney transplant patients without diabetes
Treatments studied
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This study tests whether a medicine called SGLT2i (a type of pill for kidney health) is safe and helpful for kidney transplant recipients who do not have diabetes. It aims to see if it can improve how the new kidney works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a kidney transplant and do not have diabetes (type 1 or 2).
- Your transplant was more than 6 months ago.
- Your kidney function (eGFR) is above 25 in the last 3 months.
- You are taking tacrolimus as part of your anti-rejection medicines.
- If you are a woman who could become pregnant, you have a negative pregnancy test and agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medication called an SGLT2 inhibitor can help prevent new-onset diabetes after a kidney transplant. It is for people who have received a kidney transplant, do not have diabetes, and are taking tacrolimus.
This trial tests semaglutide, a medicine that helps lower blood sugar, in people who develop high blood sugar shortly after a kidney transplant. It may help control blood sugar without harming the transplanted kidney, while also checking safety in this specific group.
This Phase 2 trial tests whether combining two diabetes medicines—an SGLT2 tablet and a GLP-1 shot (semaglutide)—can improve kidney outcomes and safety in people with a kidney transplant. It may help some recipients, but it also carefully checks for infection risk, diabetes complications, and pregnancy plans.
This trial is testing a medication called SGLT2i (a type of diabetes drug that also helps the heart and kidneys) in people who have received a heart transplant. It aims to see if this drug can improve health after transplant.
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
Hear when a new Kidney Transplantation Recipients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.